Login / Signup

Successful Treatment of Delayed Localized Necrotizing Inflammatory Myositis After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine: A Case Report.

Jennifer Chen LiJonathan SiglinMichael S MarshallAnat Stemmer-RachamimovSeth M BloomKimberly G Blumenthal
Published in: Open forum infectious diseases (2022)
Reported adverse reactions to the mRNA-1273 vaccine (Spikevax, Moderna Inc) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) range from mild, local delayed cutaneous reactions to rarer, more serious reactions such as myocarditis. Here, we describe the presentation and successful treatment of delayed, localized necrotizing inflammatory myositis following a third dose of the mRNA-1273 SARS-CoV-2 vaccine. To our knowledge, this is the first report of biopsy-confirmed, delayed inflammatory myositis after administration of an mRNA-1273 SARS-CoV-2 vaccine booster.
Keyphrases
  • respiratory syndrome coronavirus
  • sars cov
  • coronavirus disease
  • oxidative stress
  • interstitial lung disease
  • binding protein
  • healthcare
  • myasthenia gravis
  • rheumatoid arthritis
  • case report